NCT00911313View on ClinicalTrials.gov

Letrozole or Combined Metformin Clomiphene Citrate (CC) for Women With CC Resistant Polycystic Ovary Syndrome

NACompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Letrozole tablets (Femara; Novartis Pharma, Switzerland)

2.5 mg letrozole daily from day 3 of the menses for 5 days

DRUG

metformin HCl (Cidophage®; CID,Cairo, Egypt)

metformin HCl 1500 daily for 6-8 weeks

DRUG

CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)

150 mg CC for 5 days starting from day 3 of menstruation

Trial Locations (1)

35511

Mansoura University Hospitals,OB/GYN department, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT00911313 - Letrozole or Combined Metformin Clomiphene Citrate (CC) for Women With CC Resistant Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter